logo
Godavari Biorefineries secures EU patent for anti-cancer molecule

Godavari Biorefineries secures EU patent for anti-cancer molecule

Fibre2Fashion3 days ago
Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB) announced that its European patent for a novel anti-cancer molecule has been validated in Spain, the United Kingdom, and as a Unitary Patent covering multiple EU member states. This milestone underscores the company's growing presence in high-impact scientific innovation, led by its dedicated Anti-Cancer Research Segment.
Godavari Biorefineries' anti-cancer molecule patent has been validated in Spain, the UK, and as a Unitary Patent in the EU. Now in Phase 1a trials, the molecule shows promise against various cancers. This milestone boosts GBL's scientific innovation presence, led by Sathgen Therapeutics, and supports its broader push into biotech alongside its core bio-based businesses.
The patented molecule has demonstrated efficacy against both cancer cells and cancer stem cells, marking a promising advance toward more targeted and effective cancer therapies. It has shown potential in the treatment of various cancers, including breast and prostate cancer, with encouraging efficacy and safety profiles in preclinical animal studies. The molecule is currently in Phase 1a clinical trials to assess safety in human patients with advanced solid tumors as well as in healthy volunteers.
"This patent validation marks a significant milestone in our journey toward advancing original, high-quality scientific research," said Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited. "It reflects the dedication of our teams and our aspiration to contribute meaningfully to global knowledge and innovation."
Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company's clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its investment in translational research that addresses some of the world's most urgent health challenges.
This development highlights GBL's growing diversification into advanced scientific domains, complementing its leadership in ethanol, bio-based chemicals, and renewable materials produced from agricultural feedstocks. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged.
ALCHEMPro News Desk (HU)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

IT, oil stocks drag indices slip into red zone
IT, oil stocks drag indices slip into red zone

Hans India

time23 minutes ago

  • Hans India

IT, oil stocks drag indices slip into red zone

Mumbai:Stock markets closed lower on Wednesday due to selling in IT and oil & gas shares as investors turned cautious ahead of the start of earnings season and mixed global trends. Dragged by late selling, the 30-share BSE Sensex fell by 176.43 points or 0.21 per cent to settle at 83,536.08. During the day, it lost 330.23 points or 0.39 per cent to 83,382.28. The 50-share NSE Nifty declined 46.40 points or 0.18 per cent to end at 25,476.10. From the Sensex firms, HCL Tech, Tata Steel, Tech Mahindra, Reliance Industries, Bharat Electronics and ICICI Bank were among the laggards. Bajaj Finance, Hindustan Unilever, UltraTech Cement and Power Grid were among the gainers. 'Indian key indices remained largely range-bound, while domestic consumption themes continued to anchor investor sentiment. Despite global trade tensions and commodity tariffs, investor focus is increasingly shifting toward domestic earnings and structural growth drivers, including a likely sequential recovery in urban demand and a pickup in infrastructure-led spending,' Vinod Nair, Head of Research, Geojit Investments Limited, said. The US has extended the suspension of its April 2 reciprocal tariffs until August 1. Shares of mining giant Vedanta dropped 3.38 per cent to end at Rs 440.80 on the BSE after US short seller Viceroy Research released a report charging billionaire Anil Agarwal's mining conglomerate to be 'financially unsustainable' and posing a severe risk to creditors. Viceroy said it was shorting the debt stack of Vedanta Resources, the parent company and majority owner of Mumbai-listed Vedanta Ltd, as it released the 85-page report. Responding to the report, Vedanta in a statement said, 'The report is a malicious combination of selective misinformation and baseless allegations to discredit the Group'. 'Markets traded in a volatile but in a narrow range and ended marginally lower, extending the ongoing consolidation phase. While the tariff-related concerns linger, the focus now shifts to the earnings season, with IT major, TCS, scheduled to announce its results on Thursday, July 10,' Ajit Mishra – SVP, Research, Religare Broking Ltd, said. The BSE SmallCap gauge climbed 0.45 per cent while midcap index dipped 0.05 per cent. Among BSE sectoral indices, oil & gas dropped the most by 1.41 per cent. Metal (1.41 per cent), realty (1.40 per cent), BSE Focused IT (0.80 per cent), teck (0.71 per cent) and IT (0.67 per cent) were among the losers. FMCG, auto, consumer durables, services, consumer discretionary and dinancial services were the gainers.

TATA AutoComp, Skoda Group form JV
TATA AutoComp, Skoda Group form JV

Hans India

time23 minutes ago

  • Hans India

TATA AutoComp, Skoda Group form JV

New Delhi: Auto components maker TATA AutoComp and Skoda Group on Wednesday announced the formation of a joint venture to manufacture railway propulsion systems and components in India envisaging 'multi-million euro investment' in the country. This partnership is aimed at supporting the growing Indian railway and mobility markets, TATA AutoComp said in a statement. Skoda Group is a leading European manufacturer of components and vehicles for public transport. On the other hand TATA AutoComp has a significant market position in providing systems and components for electric vehicles. 'This partnership will diversify TATA AutoComp's portfolio and strengthen its capability in railway and metro segment,' the company said. TATA AutoComp further said 'it aims to bring sustainable innovations in mobility solutions at an affordable cost, specifically catering to rolling stock in India.' The new company, jointly owned by the two partners, will focus on manufacturing converters, drives and auxiliary converters for medium high-speed and regional trains, metros and light rail vehicles, the statement said. 'Manufacturing operations will be based in India. The joint venture involves a multi-million-euro investment and is expected to bring economic and technological benefits to the region,' it added. Tata AutoComp Vice-Chairman Arvind Goel said: 'Our collaboration with Skoda Group is set to enhance our footprint in the Indian Railway and Metro sector by enabling the introduction of state-of-the-art electrical propulsion systems and components.'

Ambuja Cements shares in focus after ACC commissions 1.5 MTPA grinding unit in Jharkhand
Ambuja Cements shares in focus after ACC commissions 1.5 MTPA grinding unit in Jharkhand

Economic Times

time25 minutes ago

  • Economic Times

Ambuja Cements shares in focus after ACC commissions 1.5 MTPA grinding unit in Jharkhand

Shares of Ambuja Cements will be in focus on Thursday after the company announced that its subsidiary, ACC Limited, has successfully commissioned a 1.5 million tonnes per annum (MTPA) brownfield grinding unit at its Sindri plant in Jharkhand. ADVERTISEMENT With this commissioning, Ambuja Cements' total installed cement capacity has increased to 104.45 MTPA, the company said in a regulatory filing. 'This development marks a significant milestone in the company's journey of growth and excellence,' it added. Last month, Ambuja had commissioned a 2.4 MTPA brownfield expansion at its Sankrail unit in West Bengal, which had pushed its capacity to 102.95 MTPA. Also Read: These 10 debt-free penny stocks rallied 75-355% in 1 year. Do you own any? For the March 2025 quarter, Ambuja Cements reported a 75% year-on-year (YoY) rise in standalone net profit to Rs 929 crore, while revenue from operations grew 19% YoY to Rs 5,670 crore. ADVERTISEMENT On a consolidated basis, however, profit after tax declined 9% YoY to Rs 956 crore, compared to Rs 1,051 crore in the same quarter last year. Consolidated revenue rose 12% YoY to Rs 9,872 stood at Rs 1,868 crore, up 10% YoY, with margins steady at 18.9%. EBITDA per tonne came in at Rs 1,001, excluding a one-time government grant recorded in the previous quarter. ADVERTISEMENT Also Read: Is the chemical sector entering a new supercycle? Top stocks already up 35–135% in 2025 According to Trendlyne, the average analyst target price for Ambuja Cements is Rs 623, implying an upside of just over 6% from current levels. The stock holds a 'Buy' rating from 38 analysts. ADVERTISEMENT Ambuja shares closed 0.1% lower at Rs 590.7 on Wednesday on the BSE, while the benchmark Sensex slipped 0.21%. The stock has gained 12% in the past six months and is up 10% year-to-date. Ambuja Cements' market capitalisation currently stands at Rs 1.45 lakh crore. (Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store